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Dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS) is a common disorder of the tear film caused by decreased
tear production or increased evaporation and manifests with a wide variety of signs and symptoms. The present review from
interpretation of the literature gives detailed information on the prevalence, definition, causes, diagnostic tests, and medical
management of dry eye disease. A number of systems contribute to the physiological integrity of the ocular surface and disruption of
systemmay ormay not produce symptoms.Therefore accurate diagnosis of dry eyes with no orminimal disruption of physiological
function is necessary.Thepaper also discusses different colloidal drug delivery systems and current challenges in the development of
topical ophthalmic drug delivery systems for treatment of KCS. Due to the wide prevalence and number of factors involved, newer,
more sensitive diagnostic techniques and novel therapeutic agents have been developed to provide ocular delivery systemswith high
therapeutic efficacy. The aim of this review is to provide awareness among the patients, health care professionals, and researchers
about diagnosis and treatment of KCS and recent developments and future challenges in management of dry eye disease.
1. Introduction
Dry eye syndrome (DES) is a disorder of the preocular
tear film that results in damage to the ocular surface and
is associated with symptoms of ocular discomfort. DES is
also called keratoconjunctivitis sicca (KCS), keratitis sicca,
sicca syndrome, xerophthalmia, dry eye disease (DED),
ocular surface disease (OSD), or dysfunctional tear syndrome
(DTS), or simply dry eyes [1]. Keratoconjunctivitis sicca is a
Latin word and its literal translation is “dryness of the cornea
and conjunctiva.” It may be helpful to know that “sicca” is
part of the English word “desiccate.” The dry eye syndrome
in which the eyes do not produce enough tears is also known
as “Sjo¨gren’s syndrome” [2].
Dry eye disease is characterized by instability of the tear
film that can be due to insufficient amount of tear production
or due to poor quality of tear film, which results in increased
evaporation of the tears. Dry eye therefore can mainly be
divided into two groups, namely,
(1) aqueous production deficient dry eye disease;
(2) evaporative dry eye disease.
Insufficient tears cause damage to the interpalpebral ocular
surface and are associated with symptoms of discomfort.
The International Dry Eye Workshop (2007) defined dry eye
as a multifactorial disease of the tears and ocular surface
that results in symptoms of discomfort, visual disturbance,
and tear film instability with potential damage to the ocular
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surface. It is accompanied by increased osmolarity of the
tear film and inflammation of the ocular surface [1, 3].
DES is associated with decreased ability to perform certain
activities such as reading, driving, and computer related
work, which require visual attention. Patients experience dry
eyes symptoms constantly and severely, affecting their quality
of life [4–8].
2. Prevalence of Dry Eye
The prevalence of dry eye syndrome increases with age.
DES is a common disorder of eyes affecting a significant
percentage of the population, especially those older than 50
years of age [9, 10].Middle-aged and older adults are themost
commonly affected group because of the high prevalence
of contact lens usage, systemic drug effects, autoimmune
diseases, and refractive surgeries in these groups [11–13]. The
burden of DES will continue to increase, due to increased life
expectancy, aswell as projected population growth among the
elderly. Surveys have estimated the prevalence ofDES varying
between 5% and >30% in various age groups across different
countries and worldwide [14, 15]. The estimated number of
people affected by DES ranges from 25 to 30 million all
over the world. Research also shows that DES can affect any
race and is more common in women than in men [16, 17].
In women at the age of 50–52 when menopause usually
sets in, an imbalance occurs between the oestrogen and
androgen hormones. This excites inflammation in lacrimal
gland and ocular surface, disrupting the normal homeostatic
maintenance of the lacrimal gland and ocular surface. Up to
20% of persons with rheumatoid arthritis have KCS [18, 19].
Other individuals which are likely to be affected include
patients with Helicobacter pylori, computer users, and long-
term contact lens wearers [20, 21].
3. Tear Fluid and Composition
Dry eye is recognized as a consequence of disruption of
lachrymal functional unit. The lachrymal functional unit
consists of lachrymal glands, ocular surface including cornea,
conjunctiva, eyelids, meibomian glands, ocular nerves, and
goblet cells [22].
The tear film is composed of threemain layers.The inner-
most mucin or mucus layer is the thinnest, produced by cells
of conjunctiva.Themucus helps the overlying watery layer to
spread evenly over the eye.Themiddle or aqueous layer is the
largest, thickest layer produced by the glands of upper lids and
the accessory tear glands and contains essentially a very dilute
saltwater solution [23, 24].This layer keeps the eye moist and
helps in the removal of any dust, debris, or foreign particles.
Defects of this layer cause DES in most cases [25, 26]. The
uppermost layer of tear film is a very thin layer of lipids.
These lipids are produced by the meibomian glands and the
glands of Zeis (oil glands in the eyelids). This layer helps
to decrease evaporation of the watery layer beneath it. The
mucous also reduces the surface tension between the lipid
layer of the tear film and the water layer, thus contributing
to the stability of the tear film [27–29]. The tear fluid also











Figure 1: Causes of dry eyes.
consists of complex mixture of proteins, immunoglobulins,
mucins, electrolytes, cytokines, lysozymes, lactoferrin, and
growth factors [23, 24, 30]. Lysozyme may act synergistically
with IgA in lysis of bacteria. Tears also contain lactoferrin,
which has some antibacterial effect [31, 32]. Average glucose
concentration of the tears is 2.5mg/dL and average tear
urea level is 0.04mg/dL. Electrolytes such as K, Na, and Cl
occur in higher concentration in the tears than in the blood.
Osmolarity of tears is 309mOsm/liter [24, 33]. Average pH of
the tears is 7.25 and refractive index of the tear film is 1.336
[30, 33, 34].
4. Causes for Dry Eye Syndrome
Causes for DES include decreased tear production, excessive
tear evaporation, and abnormality in the production of
mucus or lipids of tear layer [24, 25, 31] (Figure 1). A previous
report by Lemp in 1995 classified KCS into tear deficient
and evaporative dry eyes [25]. Tear deficient dry eye due to
poor production of tears by the tear glands is found in older
patients, in postmenopausal women, and in patients with
autoimmune diseases like primary Sjo¨gren’s syndrome and
rheumatoid arthritis [13, 16, 19].
Dysfunction of lacrimal functional unit causes changes in
composition of the tear fluid and tear film stability [35–37]
leading to inflammation of ocular surface. Eye does not pro-
duce adequate tears as anti-inflammatory component of eye
is lacking and irritation of eye is not controlled. This causes
activation of inflammatory cells including T-lymphocytes by
immune system of body. T-cells release cytok- ines which
causes inflammation of ocular surface and glands, thereby
resulting in abnormal tears and dry eye symptoms [38, 39].
An increase in osmolarity of the aqueous layer is suggested as
a global feature of DES and is known to trigger inflammation,
damaging the ocular surface [25, 31].
Sjo¨gren’s syndrome (SS) is characterized by the combi-
nation of aqueous tear deficiency (ATD) and dry mouth
(xerostomia) [2]. All cases of SS are characterized by
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Severity grade 1 or mild 
DED
Severity grade 2 or 
moderate DED
Severity grade 3 or
severe DED
∙ Symptoms of DED in normal
environmental conditions
∙ Tests such as hyperosmolarity,
hypolysozyme positive
∙ Epithelial erosion, punctate keratopathy,
filamentary keratitis
∙ Short TBUT
∙ Permanent sequelae such as corneal ulcer
and opacity in addition to the above symptoms 
∙ Commonly observed in untreated patients
Figure 2: Classification of dry eye disease.
a progressive infiltration of the lacrimal and salivary glands by
lymphocytes, leading to disorganization of the normal gland
architecture and consequent loss of function [24, 40].
Patients with non-Sjo¨gren’s syndrome are associated with
disease of the tear gland such as vitamin A deficiency,
trachoma, sarcoidosis, and lymphoma [41].
In case of evaporative dry eyes, eyes dry out because of
greater tear evaporation as in case of reduced blinking and
lid surface anomalies. Environmental factors such as central
heating, dry climate, air pollution, wind, chemical burns,
contact lens wear, or reduced blinking because of driving,
watching TV, and computer work can affect the tear film
and proceed up to infection, corneal ulcer, and blindness
[42–44]. Evaporative loss of tear fluid and dry eyes are
usually associated with inadequate lipid layer. The lipid layer
stabilizes and retards evaporation of the underlying aqueous
layer [45]. Rosacea, blepharitis, andMGD (meibomian gland
dysfunction) aremajor causes of evaporative dry eyes. In case
of ocular disease rosacea, there is abnormal production of
lipids due to meibomian gland dysfunction [46].
5. Symptoms
The main symptom of dry eyes is dry and gritty feeling in
the eyes.The additional symptoms include burning or itching
in the eyes, foreign body sensation, excess tearing, pain and
redness of the eyes, and photophobia in some cases [47, 48].
Sometimes it is also associated with a stringy discharge and
blurred, changing vision. Symptoms are found to worsen in
dry weathers, with low humidity and higher temperatures
[49]. DED is classified into three grades of clinical severity
[1, 50] and the main symptoms are shown in Figure 2.
6. Diagnosis of Dry Eyes Syndrome
Diagnostic tests are used for different purposes such as
assessing eligibility in a clinical trial and monitoring changes
quantitatively [3, 51–53], diagnosing in every day clinical
practice by ophthalmologists, and characterizing dry eye as
part of clinical syndrome such as Sjo¨gren’s syndrome [3, 49,
54]. Recently tests such as tear film breakup time (TBUT),
epithelial staining, and ocular surface disease index (OSDI)
are used to find correlation between ocular surface disorder,
for example, meibomian gland dysfunction, dry eyes, and
lifetime computer use/comfort levels [55]. The diagnosis
of keratoconjunctivitis sicca (KCS) is made by combining
information obtained from the physical examination andper-
forming diagnostic tests. Poor correlation between clinical
signs and patient symptomswould require the use ofmultiple
tests. Generally 2 or more tests are performed to permit an
absolute diagnosis of DES. Symptom questionnaires can also
be used to help establish a diagnosis of DES and to assess the
effects of treatments or to grade disease severity.
6.1. Tear Film Breakup Time (TBUT). The time required
for the tear film to break up following a blink is called
TBUT. It is a quantitative test for measurement of tear
film stability [3]. The normal time for tear film breakup is
15–20 sec. A fluorescein strip is moistened with saline and
applied to the inferior cul-de-sac. After several blinks, the
tear film is examined using a broad-beam of slit lamp with
a blue filter for the appearance of the first dry spots on the
cornea. TBUT values of less than 5–10 seconds indicate tear
instability and are observed in patients withmild tomoderate
dry eye disease [56]. TBUT can also be measured without
the addition of fluorescein to the tear film and is called
noninvasive BUT (NIBUT). It uses a grid or other patterns
directed on the precorneal tear film for observation of image
distortion and time from opening the eyes to the first sign of
image distortion is measured in seconds [57].
6.2. Epithelial Staining. In a staining method, special dyes
such as Rose Bengal, lissamine green, and fluorescein are used
[58] to determine abnormalities of surface of the eye, quality
of tear film, and severity of dryness. It is simple and easy way
to recognize the severity of the dryness. Mild cases of DES are
detectedmore easily using Rose Bengal than fluorescein stain
and conjunctiva is stained more intensely than the cornea
[49, 59]. Staining pattern can be photographed and graded
using one of several scoring systems [3].
Fluorescein pools in epithelial erosions, stains degener-
ating or dead cells, and stains the cornea more than the
conjunctiva. Rose Bengal and lissamine green stain dead,
devitalized cells as well as healthy cells with inadequate
protection [60]. Lissamine green is preferable to Rose Bengal
as it avoids the pain, discomfort, and corneal toxicity that
are associated with Rose Bengal. However it is somewhat
less sensitive and more transient and thus more difficult to
appreciate on slit-lamp examination [3].
6.3. Schirmer Test. Schirmer test quantitatively measures the
tear production by the lacrimal gland during fixed time
period [61]. The basic test is performed by instilling topical
anaesthetic and then placing a thin strip of filter paper in
the inferior cul-de-sac [52, 62]. The patient’s eyes are closed
for 5 minutes and the amount of tears that wets the paper
is measured in terms of length of wet strip. This Schirmer
II test measures tear of lacrimal gland by stimulation of
lacrimal reflex arc [63] and wetting of <15mm after 5
minutes is considered abnormal. The results are variable as
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any manipulation of the eyelid can alter the results of the
test. Further tear drainage can affect the results. Value of
less than 6mm of strip wetting in 5 minutes is accepted as
diagnostic marker for aqueous tear deficiency. The Schirmer
I test measures both basic and reflex tearing and is performed
in a similar way to basic test but without use of a topical
anaesthetic [64].
6.4. Tear Function Index (TFI). It is a more specific and
sensitive test for quantitativemeasurement of the tears [3, 52].
It evaluates the tear dynamics of production and drainage and
helps detect subjects suffering from dry eye. Its numerical
value is obtained by dividing the Schirmer II test value in
millimeters by tear clearance rate. The higher the numerical
value of TFI, the better the ocular surface. Values below 96
suggest dry eyes. It is also called Liverpool modification [65].
6.5. Tear Osmolarity. Osmolarity of normal eye is 309–
312mOsm/L and the value increases with severity of dry eye
disease. It gives qualitative information of tear production.
It is a very sensitive test but lacks specificity. Lemp et al.
[66] concluded from a multicenter study that tear osmolarity
test was the best single method for diagnosis and severity
determination of DES, when compared with other tests such
as TBUT, staining, Schirmer test, and meibomian gland
grading.
6.6. Impression Cytology. The information of etiology of the
disease can be obtained from biopsy of conjunctival and
lateral lacrimal glands [67]. Impression cytology serves as a
minimally invasive alternative to ocular surface biopsy. Pro-
gression of ocular surface changes such asmarked decrease in
goblet cell count and keratinization ismonitored by collecting
superficial layers and examined microscopically [68]. It is a
very sensitivemethod but requires proper staining and expert
microscopic evaluation.
6.7. Symptom Questionnaires. Questionnaires explore differ-
ent aspects of dry eye disease in varying depth, including
diagnosis, identification of precipitation factors, and impact
on quality of life [51, 69]. The number of questions admin-
istered in different questionnaires may range from 3 to 57.
Examples of symptom questionnaires include extensive dry
eye questionnaire (DEQ) of Begley et al. [69], questionnaire
by Schein et al. [70], and OSDI questionnaire by Schiffman et
al. [71]. A structured questionnaire to patients helps clinicians
in screening patients with potential dry eye disease. A specific
questionnaire can be selected depending on intended use
of data, for example, for diagnosis use only, for recruiting
patients to a clinical trial, or for treatment [72].
Ocular surface disease index (OSDI) questionnaire con-
tains 3 sections: section 1 is based on relative frequency of
occurrence of each symptom (e.g., gritty feeling in eye, light
sensitivity, and blurred vision), section 2 includes questions
indicating limitations on certain activities (reading, driving
at night, watching television), and section 3 is based on effect
of environmental conditions (wind, low humidity, and air
conditioning) on eyes [73].
6.8. Fluorophotometry. This method is costly and uses the
decay of sodium fluorescein for measurement of tear flow
and volume.The tear turnover rate, defined as the percentage
by which the fluorescein concentration in tears decreases
per minute after instillation, is also reduced in patients
with symptomatic DES [49, 54]. Delayed clearance has been
associated with increased tear cytokine concentration, which
may contribute to chronic inflammation [62].
6.9. Tear Fluid Protein Immunoassays. The protein compo-
nent of tears may be quantified by measuring tear lysozyme,
tear lactoferrin, epidermal growth factor (EGF), aquaporin 5,
lipocalin, and immunoglobulin A (IgA) concentrations with
enzyme-linked immunosorbent assay (ELISA) techniques, as
well as tear-film osmolarity [63, 74, 75]. The normal values
for total lysozyme reactivity and lactoferrin are given in
Table 1. The tear lysozyme accounts for 20–40% of total tear
protein and lysozyme reactivity test is used for quantification;
however itsmain disadvantage is its lack of specificity in some
eyes disorders. Colorimetric solid-phase and ELISA tech-
niques are used for lactoferrin analysis. Table 1 summarises
established normal values for selected tests.
6.10. Tear Ferning Test (TFT). The tear ferning test (TFT) can
be used to help diagnose the quality of tears/mucin, DES,
and hyperosmolarity. A drop of tear fluid is collected from
the lower eyelid and then placed onto a microscope slide and
allowed to dry by evaporation. Different forms of branching
crystallization patterns are observed and classified. The test
diagnoses dry eyes on the basis of the ferning patterns [76].
6.11. Other Tests. Meibomian gland dysfunction (MGD) is
diagnosed by techniques such as meibometry, meibography,
or meiboscopy [77]. Tear evaporation is tested by means of
evaporimetry. Meniscometry is used to help diagnose aque-
ous rear deficient dry eyes. Lacrimal gland orminor (salivary)
gland biopsymay be used for diagnosis of Sjo¨gren’s syndrome.
Histopathological findings also help to characterize DES and
MGD. Reduced tear flow and flushing action are determined
by microscopic examination of tear film debris.
The results of diagnostic tests discussed above poorly cor-
relate with symptoms [14]. Though the literature emphasizes
hyperosmolarity as a global mechanism of DED, indicating
tear osmolarity measurement as a gold standard [61, 78]
for diagnosis, unfortunately no single qualitative/quantitative
test is capable of assessing integrity of tear film and severity of
disease. Therefore the results of multiple abnormal tests can
be used to diagnose DES accurately.
7. Medical Management
The treatments of keratoconjunctivitis are varied. The goals
of treatment are to relieve the symptoms of dry eye, improve
the patient’s comfort, return the ocular surface and tear film
to the normal state, and, whenever possible, prevent corneal
damage [3]. Treatment may range from education, environ-
mental or dietary modifications, artificial tear substitutes,
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Table 1: Diagnostic tests and normal values.
Test Normal values
Tear film breakup time (TBUT) >10 sec
Noninvasive breakup time (NIBUT) 40 sec–60 sec
Epithelial staining No visible staining
Schirmer test (basic) >5mm after 5 minutes
Schirmer I test (without topical anesthesia) >10mm after 5 minutes
Schirmer II test/Jones test (with anesthesia) >15mm after 5 minutes
Tear function index >96
Tear osmolarity <312–318mOsm/L
Impression cytology Normal appearance of cells
Tear fluid protein immunoassay Total lysozyme reactivity TLR <1.0
Lactoferrin 1.42mg/mL (abnormal value <1)
Table 2: Artificial tear products.
Brand name Description Manufacturer
Tears Naturale Forte Lubricant Eye Drops Contains special preservative, Polyquad
Alcon Inc.Tears Naturale P.M. eye ointment Lubricant for night time protection
Systane Ultra lubricant Demulcent matrix of HP-guar and borate
Refresh Tears Drops CMC sod. 0.5%w/v
Allergan India Pvt. Ltd.
Refresh Endura (for long-term relief) Contains castor oil to replenish lipid components oftear film, preservative-free
Refresh Celluvisc Contains CMC sod. 1%w/v; gel-like consistency maycause blurred vision
Refresh Liquigel Gel drops, CMC sod. 1%w/v, and longer duration ofaction
Tear Plus lubricant drops Contains PVA and PVP
Refresh contacts For dryness and irritation associated with contact lenses
Advanced eye relief environmental
lubricant Eye drops contain propylene glycol and glycerine
Bausch & Lomb Inc.Advanced eye relief lubricant ointment For lubrication during night time
Soothe XP Contains mineral oil and an advanced lipid restorativecalled Restoryl
GenTeal drops and gel Hydroxy propyl methyl cellulose Novartis (I) Ltd.
Hypo Tears Plus eye drops Hydroxy propyl methyl cellulose
punctal plugs, and topical and/or systemic anti-inflammatory
medications to surgery.
7.1. Artificial Tears. Artificial tears are lubricant eye drops
used to treat the dryness and irritation associated with defi-
cient tear production in KCS.The lubricant tears are available
as OTC products and usually are the first line of treatment.
Mild disease conditions require the application of lubricant
drops four times a day while severe cases need greater
frequency (10–12 times a day) of administration. These OTC
products mainly vary in their ingredients, indications, and
availability of preservatives. Ingredients such as cellulose
and polyvinyl derivatives, chondroitin sulfate, and sodium
hyaluronate determine their viscosity, retention time, and
adhesion to ocular surface [79].
The increase in viscosity of teardrops prolongs the dura-
tion of action; however it results in temporary blurred vision
[80]. Preservatives are added to multidose containers of
artificial tears to reduce the risk of bacterial contamination
and to prolong shelf-life. Many ophthalmic products con-
tain preservatives and risk of adverse effects increases with
frequency of their administration per day and also duration
of their use [81]. The clinician should take into account
the sensitivity of patient to preservatives, frequency of use,
severity of disease, contamination risk with preservative-free
product, and costwhile recommending artificial tear product.
Table 2 lists the brand names of few widely used artificial
tear products available in the market. “Refresh Tears” by
Allergan and “Tears Naturale” and “Bion Tears” by Alcon are
few excellent preservative-free artificial teardrops available in
the market [81]. Many ophthalmologists use other treatments
such as cyclosporin, corticosteroids, and tetracycline in
conjunction with artificial tears, in moderate to severe forms
of dry eyes, to reduce signs and symptoms. Lubricating tear
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ointments can be used during the day, but they generally
are used at bedtime due to poor vision after application. An
artificial tear insert such as Lacrisert which contains hydroxyl
propyl cellulose can also be used every morning [33].
7.2. Autologous Serum Eye Drops. Autologous serum eye
drops contain different essential tear components such as
hepatocyte growth factor, epidermal growth factor, vitamin
A, and fibronectin that are important for maintaining healthy
ocular surface. All these components are not available in the
commercial products and use of these eye drops for treatment
of KCS is controversial [82].
7.3. Nonsteroidal Anti-Inflammatory Drugs and Antibiotics.
NSAID drops containing drugs such as diclofenac sodium
and ketorolac reduce the inflammation associated with DES.
Ophthalmic ointments containing antibiotics such as ery-
thromycin and bacitracin are used for treatment of meibo-
mian gland dysfunction [83].
Topical ophthalmic aqueous solution of tetracycline has
been developed for chronic DES. Tetracyclines are used in
DES primarily for their anti-inflammatory effects rather than
antibacterial actions [64, 84].
7.4. Punctal Plugs. A small medical device called “punctal
plug” is inserted into puncta of an eye to block the duct so
as to prevent nasolacrimal drainage of tears from eye and
thereby dry eyes. Clinical studies have shown that the punctal
plugs, as means of occlusion, improve DED symptoms and
signs [85]. Punctal plugs are usually reserved for people
with moderate to severe KCS and use of artificial tears is
necessary after punctal plug insertion. Patient education and
close follow-up are recommended to detect plug loss and
ensure adequate control of the disease.
7.5. Corticosteroids. Topical corticosteroids, such as lotepred-
nol etabonate, dexamethasone, prednisolone, and fluo-
rometholone, are found to be effective in inflammatory
conditions associatedwith KCS and these are approved by the
FDA for treating inflammatory conditions of the conjunctiva,
cornea, and anterior globe [64, 86, 87]. They are generally
recommended for short-termuse as prolonged usemay result
in adverse effects such as ocular infection, glaucoma, and
cataracts.
7.6. Cyclosporin. Cyclosporin A is effective in a number
of ocular immune pathologies. Systemic administration of
drug is used in treatment of local ophthalmic conditions
involving cytokines, such as corneal graft rejection, autoim-
mune uveitis, and dry eye syndrome; however it induces
severe renal and cardiovascular complications [88]. Local
administration avoids the various side effects associated with
systemic delivery giving this drug a wide safety profile.
Topical cyclosporine A is the first FDA approved medication
indicated for treatment of patients with aqueous production
deficient dry eye and is better for long-term treatment. It is
marketed as “Restasis” 0.05% ophthalmic topical emulsion
and as “Cyclomune” by Sun Pharma in India.
It is a highly specific immunomodulator that prevents
activation of T lymphocytes and significantly decreases levels
of inflammatory cytokines in the conjunctival epithelium
with an increase in goblet cells [64, 89]. It also inhibits
mitochondrial-mediated pathways of apoptosis [90].
The clinical study demonstrating the use of topical cyclos-
porine for the treatment ofmild,moderate, and severe dry eye
disease unresponsive to artificial tears therapy concluded that
topical cyclosporine has shown beneficial effects in all cate-
gories of dry eye disease [91]. Because of highly hydrophobic
properties, topical formulation of cyclosporin A is prepared
using different vegetable oils, resulting in a poor local tol-
erance by the patients [92] and low bioavailability. Multiple
studies have supported the use of topical cyclosporine to treat
DED caused by insufficient tear production [93, 94]. The use
of colloidal carriers such as micelles, nanoparticles, and lipo-
somes is a promising approach to obtain better tolerance and
ocular bioavailability and is discussed separately (Section 8)
for treatment of DES. Table 3 lists few marketed products
other than artificial tears for DED treatment.
7.7. Vitamin A. Vitamin A is an essential nutrient present
naturally in tear film of healthy eyes. Vitamin A plays an
important role in production of the mucin layer, the most
innermost lubricating layer of tear film that is crucial for
a healthy tear film. Vitamin A deficiency leads to loss of
mucin layer and goblet cell atrophy [1, 95]. Vitamin A drops
protect the eyes from free radicals, toxins, allergens, and
inflammation. Topical retinoic acid therapy in conjunction
with systemic administration of vitamin A has been investi-
gated to treat xerophthalmia [96]. Effective amount of one or
more retinoids alone may be dispersed in a pharmaceutically
acceptable ophthalmic vehicle and topically applied for effec-
tive treatment of dry eye disorders.
7.8. Omega 3 Fatty Acids. Oral supplementation with essen-
tial fatty acids (EFAs) is suggested nowadays by ophthal-
mologists [64, 97]. EFAs are the precursors of eicosanoids,
locally acting hormones involved in mediating inflammatory
processes [98]. Essential fatty acids may benefit DED patients
by reducing inflammation and by altering the composition
of meibomian lipids. Clinicians may suggest dietary intake
of n-3 fatty acid to help relieve DES [99]. Some examples of
omega 3 gel caps marketed specifically for dry eyes include
Thera Tears and Bio Tears.
The study performed by Rashid et al. at theMassachusetts
Eye Research Institute demonstrated for the first time the
benefit of topical application of a particular fatty acid in treat-
ing the signs of dry eye syndrome. Topical alpha-linolenic
acid (ALA) treatment has been found to decrease signs
of dry eye and inflammatory changes significantly at both
cellular and molecular levels [100]. Thus topical application
of ALA may be a novel therapy to treat the clinical signs and
inflammatory changes in KCS.
Advances in Pharmaceutics 7
Table 3: Few marketed preparations for treatment of keratoconjunctivitis sicca.
Manufacturer Brand Content Delivery system andindication
Allergan, Inc.
Restasis (by prescription) Cyclosporin A 0.05%w/v Oil-based emulsionDED treatment
Refresh Optive Contains 2 osmolytes L-carnitine anderythritol and CMC sodium 5mg Eye drops
Sun Pharma Ind. Ltd. Cyclomune Cyclosporin A 0.05%w/v DropsDED treatment
Bausch & Lomb Inc. Lotemax Loteprednol etabonate 0.5% Suspension drops (steroid)for short-term therapy
Novartis Ltd. Voltaren Diclofenac sodium ophthalmic solution) 0.1% Drops
FDC Ltd. ZO-D eye drops Ofloxacin and dexamethasone Drops
Allergan India Pvt. Ltd.








Ocusoft, Inc. RetaineMGD Cationic O/W emulsion technology
Hypotonic emulsion provides
lubrication
Otsuka Pharmaceuticals Mucosta ophthalmicsuspension UD2% Rebamipide
Marketed in China, Japan,
Indonesia, Malaysia, and
Thailand
Advanced Vision Research Thera tears nutrition Omega 3 fatty acids Gel capsules
8. Colloidal Carrier Systems for
Treatment of KCS
The rationale for the use of microparticulate systems for the
delivery of ophthalmic drugs is based on possible entrap-
ment of the small particles in the ocular mucus layer and
the interaction of bioadhesive polymer chains with mucins
inducing a prolonged residence and slow drainage [101].
Colloidal carriers are promising systems among a variety of
topical drug delivery systems as they fulfill the requirements
such as nontoxicity, ease of application as drops, drug
loading capacity, possibility of drug targeting, controlled
release characteristics, and chemical and physical storage
stability [102]. Colloidal carriers are small particles of 100–
400 nm in diameter. Colloidal systems including liposomes
and nanoparticles have the convenience of a drop, which
is able to maintain drug activity at its site of action and is
suitable for poorly water-soluble drugs [103].
Lipid based ophthalmic drug delivery systemsmay offer a
number of advantages for use in treatment of KCS. Lipophilic
matrices are not susceptible to erosion and drug encapsulated
in small lipid particle ensures close contact and selective
drug delivery to cornea and conjunctiva. Examples of carrier
systems include liposomes, solid lipid nanoparticles, lipid
suspensions and emulsions, lipid microbubbles, and lipid
microspheres [104, 105].
Liposomes are the microscopic vesicles composed of
one or more concentric lipid bilayers, separated by water
or aqueous buffer compartments with a diameter rang-
ing from 25 nm to 100 𝜇m. Adherence to the corneal or
conjunctival surface can be improved by dispersion of the
liposomes in mucoadhesive gels or coating the liposomes
with mucoadhesive polymers [106]. Lipospheres are solid
microparticles (0.2–100 𝜇m), composed of solid hydrophobic
fat core stabilized by amonolayer of phospholipidsmolecules.
Prodispersion liposphere formulation of cyclosporine has
been prepared and its topical use in treatment of DES can be
investigated [93].
Microspheres and nanoparticles have important potential
applications for site specific drug delivery. A number of stud-
ies deal with the preparation and application of ophthalmic
drugs loaded to micro- and nanospheres. Bioadhesive PLGA
and lipid microspheres have been developed to prolong
residence time of cyclosporin A in preocular area [44, 107].
A novel topical polymeric micelle formulation based on
methoxy poly(ethylene) glycol- (MPEG-) hexyl-substituted
poly(lactides) (hexPLA) has been shown to provide a selec-
tive delivery of cyclosporine A into the cornea, avoiding
systemic absorption and without compromising the ocular
surface stability [108].
Nanoparticles are colloidal particles ranging in size from
10 nm to 1000 nm. Formulations containing drug loaded
nanoparticles such as polymeric and lipid nanoparticles
have been prepared to obtain sustained ophthalmic delivery.
Cyclosporine A loaded solid lipid nanoparticles for topical
ophthalmic applications have been prepared by high shear
homogenization and ultrasound method [94]. Drug loaded
polymeric nanoparticles (DNPs) are subnanosized colloidal
structures composed of synthetic or semisynthetic polymers
offering favourable biological properties such as biodegrad-
ability, nontoxicity, biocompatibility, and mucoadhesiveness.
These submicron particles are better than conventional oph-
thalmic dosage forms to enhance bioavailability without
blurring the vision [109].
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9. Current Challenges and Future Aspects
Dry eye syndrome is the most common ophthalmic mani-
festation and untreated dry eye can cause increased risk of
ocular infection, corneal ulcer, and blindness. The clinical
diagnosis of dry eye is challenging due to extensive variety
of signs and symptoms and the ambiguity in the etiology
and pathophysiology of the disease. Unclear symptoms could
confuse the clinician with symptoms of other condition, such
as conjunctivochalasis (which can easily induce an unstable
tear film) or delayed tear clearance (which is a frequent cause
of ocular irritation) [110].
Conventional tests for diagnosis include Schirmer test,
TBUT, and ocular staining; as mentioned above, some of
them have low degree of standardization and some are
invasive. The invasive nature of some diagnostic tests can
make interpretation challenging. A tear film is a dynamic,
open system subject to numerous internal and environmental
variations leading tomisinterpretations of the obtained result
[74]. Recent studies have shown that less than 60% of subjects
with other objective evidence of DED are symptomatic [111].
Thus the use of symptoms alonewill result inmissing a signif-
icant percentage of DED patients. Clinically, osmolarity has
been shown to be the best single metric for diagnosis of dry
eyes and is directly related to increasing severity of disease.
Clinical examination and other assessments determine the
subtype of disease. In conclusion, an accurate testing and
differential diagnosis of dry eye which is crucial for medical
management of disease are difficult and results of multiple
tests measuring tear volume and biological components have
been used by ophthalmologists to diagnose KCS accurately.
Therefore the clinicians play challenging role in identification
of symptoms of dry eye, selection of appropriate diagnostic
tests and products, interpretation, and instructing patients on
the proper use of medications.
Ophthalmic drugs constitute a prominent segment of
the global pharmaceutical market, with sales of over $20
bn. Accordingly, the number of pharmaceutical industries
has tendency towards the development of new drugs for
DED to control the inflammation or to stimulate mucin and
tear secretion. Current available therapies such as lubricants
and anti-inflammatory drugs alleviate symptoms and reduce
signs of DED; however the underlying cause of disease
remains unattended. A number of drugs and different deliv-
ery systems of existing drugs are under development or in
preclinical and clinical research pipeline [106–109]. In this
section of review, we also discuss recently marketed novel
medications and few new drugs under clinical trials that may
find the way for marketing.
Most exciting drugs in R&D pipeline include diquafosol
and rebamipide. Diquafosol (INS 365) acts by stimulating
tear components and rebamipide, an amino acid analogue
of quinolinone causes mucin secretion [112, 113]. Jumblatt
and Jumblatt demonstrated that functional P2Y2 nucleotide
receptors of rabbit and human conjunctival cells are stim-
ulated by diquafosol, thereby stimulating mucociliary clear-
ance and hydration of mucosal surface [114]. Clinical studies
conducted by Santen Pharmaceutical Co., Ltd. demonstrated
the effectiveness of diquafosol at an optimal dose of 3%
six times a day [115]. Topical administration of diquafosol
was shown to be safe and effective in alleviating signs and
symptoms of DES as demonstrated with Schirmer test and
corneal staining.
Some drugs used to treat gastric ulcers also stimulate
the secretion of mucin like substances of cornea in animal
experiments, for example, rebamipide and gefarnate. The
drug rebamipide was launched for the treatment of dry eye
syndrome in Japan in 2012 asMucosta ophthalmic suspension
UD2%. It increases the level of mucin in the tear film
covering the conjunctiva and cornea [116]. A comparison
of 2% rebamipide ophthalmic suspension with 0.1% sodium
hyaluronate in a randomized multicenter Phase 3 study
showed marked improvement in signs and symptoms of
DED as compared to sodium hyaluronate [117]. Otsuka
Pharmaceutical Co., Ltd. in partnership with Acucela Inc.
has initiated Phase 3 clinical trial to determine the efficacy
and safety of 2% rebamipide ophthalmic suspension in US
patients with DES [118].
Gefarnate ointment on topical application to eyes in the
rabbit and cat dry eye models has been found to stimulate
in vitro secretion of mucin like glycoprotein in conjunc-
tival tissue and ameliorate corneal epithelial damage [119].
There are significant numbers of promising drugs that show
better results and lesser side effects in preclinical and clinical
trials [120–123]. SARcode Bioscience has conducted a year-
long safety study (SONATA) of lifitegrast 5% ophthalmic
solution after completion of Phase 3 trial which demon-
strated a superior reduction in the signs and symptoms of
DED [121]. Few other new drugs [122, 124] presently in
Phase 2 and 3 clinical trials for treatment of KCS include
AL-2178/rimexolone 1% (Alcon/Novartis, ClinicalTrials.gov
Identifier: NCT00471419), MIM-D3 (Mimetogen Pharma-
ceuticals, ClinicalTrials.gov Identifier: NCT01257607), ritux-
imab (IDEC Pharmaceuticals, ClinicalTrials.gov Identifier:
NCT00740948), ecabet sodium (Bausch & Lomb Inc.,
ClinicalTrials.gov Identifier: NCT00667004), sirolimus or
rapamycin (Santen Pharmaceutical, ClinicalTrials.gov Iden-
tifier: NCT00814944), ESBA-105 (Alcon and ESBATech,
ClinicalTrials.gov Identifier: NCT01338610), RX-10045
(Resolvyx Pharmaceuticals, ClinicalTrials.gov Identifier:
NCT00799552), CF 101 (OphthaliX Company-Can-Fite
BioPharma, ClinicalTrials.gov Identifier: NCT01235234),
DE-101/rivoglitazone (Santen pharmaceuticals, Clinical-
Trials.gov Identifier: NCT01118754), difluprednate (Alcon,
ClinicalTrials.gov Identifier: NCT01276223), RGN-259/
thymosin beta 4 (RegeneRx Biopharmaceuticals, Clinical-
Trials.gov Identifier: NCT01387347), and cyclosporine
(Restasis X) (Allergan, ClinicalTrials.gov Identifier:
NCT02013791).
Most of these potential new drugs center their action
towards controlling inflammation and restoring normal
amount of tears, but none of them attend the main cause of
disease. Thus there is a need for effective therapeutic agents
that target the causative mechanism of disease. Possibility
of use of old drugs (e.g., rebamipide) for new use in DED
treatment should be considered after understanding themain
cause of disease andmechanism of action of old drug as it will
result in reduced R&D cost and approval time. FDA approval
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is another challenge for candidate DED drugs. A number of
companies failed in securing FDA approval for new dry eye
drugs mainly in the United States [124]. Lack of clarity in
symptoms evaluation or insufficient diagnosis data is one of
the reasons for frequent failure. A very few dry eye agents pass
successfully through tight clinical trials regulations of USA as
compared to Asia and Europe. Rebamipide, being developed
for dry eye syndrome in the United States, is marketed in
Japan under the trade name Mucosta by Otsuka Pharma-
ceutical [118]. Thus there is a need for better understanding
of the FDA approval system of different countries including
protocol development, the inclusion/exclusion of signs and
symptoms, and patient selection. Patients with less disease
variability should be selected after considering type of dry
eyes, severity level, and other factors, namely, age, gender,
lifestyle, and history of poor therapeutic response.
The current treatment is based on the use of topically
applied artificial tears: tear retention management, stimula-
tion of tear secretion, and use of anti-inflammatory drugs
[125, 126]. New therapeutic strategies and novel drug delivery
systems using future pharmaceutical compounds designed
to reduce key inflammatory pathways and restore healthy
tear film along with incorporation of improved endpoints for
clinical trials will lead to successful management of dry eyes
or keratoconjunctivitis sicca in the future.
10. Conclusion
The overarching complexity of the dry eye disease makes
it challenging to diagnose and manage accurately. With
development of objective tests with precise diagnostic value
and minimal disruption of physiological function, accurate
diagnosis of disease is possible. Recent knowledge about
causes, symptoms, and diagnostic tests of KCS provides
better opportunities for improving medical management.
Development of new potential drugs and different colloidal
delivery systems definitely provides a ray of hope for more
effective treatment of this widely prevalent and debilitating
disease.
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